Polyvascular Patients: Are You Doing Enough to Reduce Risk of Recurrent Events?

This activity is part of CardiologyNOW: Live on June 17, 2021.


1.00 AMA PRA Category 1 Credits™, 1.00 ABIM MOC or 1.00 AANP, including 0.33 AANP Pharm

Release Date: 6/17/2021
Expiration Date: 6/17/2022

Cardiovascular Medicine, Coronary
Artery Disease, Peripheral Arterial Disease


Christian T. Ruff, MD, MPH

Elaine Hylek, MD, MPH


Cardiology expert, Christian Ruff, MD, MPH & primary care specialist, Elaine Hylek, MD, MPH will review the latest research and recommendations for patients with polyvascular disease. The faculty also will discuss patient cases that cover long-term atherothrombotic risks, chronic coronary artery disease (CAD)/peripheral artery disease (PAD), benefits of direct oral anticoagulants (DOACs), and considerations for the multidisciplinary team.

Learning Objectives

  • Evaluate long-term risks in patients with chronic coronary artery disease and/or peripheral arterial disease
  • Discuss the rationale behind combined antithrombotic regimens
  • Interpret the latest data on DOACs as mono- or combination therapy to develop strategies for treating and protecting against thrombotic events
  • Discuss limitations of various guideline recommendations for therapeutic anticoagulation in the context of recent evidence
  • Optimize anticoagulant therapy prophylactically and therapeutically across diverse and complex patient populations


Christian T. Ruff, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Investigator, TIMI Study Group
Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA

Elaine Hylek, MD, MPH
Professor of Medicine
Boston University School of Medicine
Director, Thrombosis and Anticoagulation Service
Boston Medical Center
Boston, MA


The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.

Christian T. Ruff, MD, MPH: Grant/Research Support, Consultant (Occasional) for Anthos Therapeutics, Boehringer Ingelheim, Daiichi Sankyo; Grant/Research Support AstraZeneca; Consultant (Occasional) for Bayer, Bristol Myers Squibb, Janssen, Pfizer, and Alexion.

Elaine M Hylek, MD, MPH: Honorarium Recipient Boehringer Ingelheim; Grant/Research Support recipient Bristol Myers Squibb, Anthos Therapeutics, and Janssen.

Peter Libby, MD (moderator): No relevant financial relationships disclosed.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and the North American Thrombosis Forum. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Pri-Med Institute, The Academy for Continued Healthcare Learning, and North American Thrombosis Forum. Pri-Med Institute is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.

Designation Statement

This activity is approved for 1.00 contact hour of continuing education, which includes 0.33 hour of pharmacology.

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Commercial Supporter

Janssen Scientific Affairs, LLC

Education Partner

Academy for Continued Healthcare Learning (ACHL)

North American Thrombosis Forum

Instructions for Obtaining Credit

Once you have completed the activity, please click the “next” button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 4 out of the 5 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the “submit” button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

Related Articles